|
private:micropharma
|
1546810
|
May 29th, 2019 12:00AM
|
Micropharma Limited
|
228
|
5.00
|
Open
|
Biotechnology
|
May 29th, 2019 07:54PM
|
May 29th, 2019 07:54PM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
Open
|
Biotechnology, Probiotics, Metabolic Disease, Enzymes, Cholesterol lowering
|
Open
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 17th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 16th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 15th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 14th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 13th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 12th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 11th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 10th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|
|
private:micropharma
|
1546810
|
Feb 9th, 2018 12:00AM
|
Micropharma Limited
|
195
|
5.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Company
From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
What we do
Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits.
The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.
|
|
|
|
|
|
|
|
|
|
Micropharma
|
|
Health Care Equipment & Services
|